对于阿尔茨海默病的自然基治疗材料的近期进展
Tayebeh Zivari-Ghader1, Ferzane Valioglu2, Aziz Eftekhari3,4
1Department of Medicinal Chemistry, Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran.
Heliyon
|March 4, 2024
概括
生物材料通过克服血脑屏障,为阿尔茨海默病 (AD) 提供先进的药物输送. 这些材料,包括纳米粒子和支架,显示神经发生和治疗AD病理的希望.
科学领域:
- 神经科学是一个神经科学.
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
背景情况:
- 阿尔茨海默氏症 (AD) 由于传统治疗方法的局限性以及血脑屏障的存在,给阿尔茨海默氏症带来了重大挑战.
- 有效的药物输送到中枢神经系统对于管理AD等神经退行性疾病至关重要.
- 生物材料正在探索克服这些局限性并提高治疗疗效.
研究的目的:
- 提供用于阿尔茨海默病治疗的生物材料的全面概述.
- 突出先进药物输送系统在克服治疗挑战中的作用.
- 综合当前关于基于生物材料的AD策略的知识.
主要方法:
- 对神经系统疾病中药物输送的生物材料现有文献的审查.
- 分析各种智能药物输送系统,包括pH和热触发机制.
- 探索聚合物和脂质载体,无机纳米颗粒和其他载体用于针对大脑的治疗.
主要成果:
- 生物材料,包括纳米粒子和可生物降解的聚合物,显示出跨越血脑屏障的药物运输潜力.
- 功能化的纳米载体和水凝可以准Aβ聚合并支持神经发生.
- 涉及细胞和先进生物材料的组合疗法在阿尔茨海默病治疗中显示出有前途的结果.
结论:
- 生物材料作为复杂的药物载体对阿尔茨海默病治疗至关重要.
- 智能药物输送系统提供了创新的策略,以补充当前的治疗方法.
- 进一步利用生物材料的研究为新的阿尔茨海默病范式带来了变革的潜力.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.3K
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.5K
相关概念视频
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
